Clinical trial · Interventional
Impact of Cancer on Memory Functioning: Understanding Disorders Using Approaches in Neuropsychology and Neuroimaging
NCT01332916CI-TRIAL-00014347CANMEMterminatedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): lack of patient
Summary
Brief summary (as posted)
The purpose of this study is to investigate memory problems in patients with cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Healthy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| cognitive tests and cerebral IRM | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- patients aged 45 and over group
- description
- patients aged 45 and over with breast cancer and should receive an adjuvant chemotherapy
- interventionNames
- Procedure: cognitive tests and cerebral IRM
- type
- ACTIVE_COMPARATOR
- label
- healthy volunteers (controls) aged 45 and over
- description
- healthy volunteers (controls) aged 45 and over
- interventionNames
- Procedure: cognitive tests and cerebral IRM
Primary outcomes (1)
- measure
- Assess the relationship between memory impairment and brain dysfunction
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria for patients: * Patients aged 45 and over * Patients from Grade 3 'end of primary schooling "minimum (scale Barbizet) * Non-Metastatic Breast Cancer * Adjuvant Chemotherapy: FEC, including Docetaxel Protocols * No major cognitive impairment * No previous neurological * Lack of personality disorders and psychiatric disorders evolutionary * Having signed the informed consent of study participation Inclusion Criteria for control group: * Women from the general population aged 45 and over, and matched in age and cultural level in patients * Topics of Grade 3 'end of primary schooling "minimum (scale Barbizet) * No prior cancer * No major cognitive impairment * No previous neurological * Lack of personality disorders and psychiatric disorders evolutionary * Participating in the IMAP Protocol No. ID-BCR: 2007-A00414-49 or IMAP+(n° ID RCB 2011-A01493-38)(see how the study below) have signed forms no objection and consent to study participation Exclusion Criteria: Traduction (français \> anglais) * Metastatic * Cancer of the breast other than primitive * Patients with paraneoplastic syndrome * Patients under 45 years * Patients whose achievement is below level 3 'end of primary schooling "(scale Barbizet) * Patients with adjuvant chemotherapy is associated with targeted therapy * Patients who have received other cancer treatments (chemotherapy or radiotherapy brain) * Contraindication to the implementation of an MRI (claustrophobia, metal objects in the body) * disorders of higher functions existing in the administration of chemotherapy * Neurologic earlier * Pathology psychiatric evolutionary * Refusal of participation * Patients unable to meet the cognitive tests * Drug use * Heavy drinking
References
Publications (0)
Data not yet available
No reference posted for this study.